A Non-Smad Mechanism of Fibroblast Activation by Transforming Growth Factor-beta Via C-Abl and Egr-1: Selective Modulation by Imatinib Mesylate

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2009 Jan 20

PMID 19151753

Citations 41

Authors

S Bhattacharyya

W Ishida

M Wu

M Wilkes

Y Mori

M Hinchcliff

E Leof

J Varga

Affiliations

Soon will be listed here.

Abstract

The nonreceptor protein tyrosine kinase c-Abl regulates cell proliferation and survival. Recent studies provide evidence that implicate c-Abl as a mediator for fibrotic responses induced by transforming growth factor-beta (TGF-beta), but the precise mechanisms underlying this novel oncogene function are unknown. Here, we report that when expressed in normal fibroblasts, a constitutively active mutant of Abl that causes chronic myelogenous leukemia (CML) stimulated the expression and transcriptional activity of the early growth response factor 1 (Egr-1). Mouse embryonic fibroblasts (MEFs), lacking c-Abl, were resistant to TGF-beta stimulation. Responsiveness of these MEFs to TGF-beta could be rescued by wild-type c-Abl, but not by a kinase-deficient mutant form of c-Abl. Furthermore, Abl kinase activity was necessary for the induction of Egr-1 by TGF-beta in normal fibroblasts, and Egr-1 was required for stimulation of collagen by Bcr-Abl. Lesional skin fibroblasts in mice with bleomycin-induced fibrosis of skin displayed evidence of c-Abl activation in situ, and elevated phospho-c-Abl correlated with increased local expression of Egr-1. Collectively, these results position Egr-1 downstream of c-Abl in the fibrotic response, delineate a novel Egr-1-dependent intracellular signaling mechanism that underlies the involvement of c-Abl in certain TGF-beta responses, and identify Egr-1 as a target of inhibition by imatinib. Furthermore, the findings show in situ activation of c-Abl paralleling the upregulated tissue expression of Egr-1 that accompanies fibrosis. Pharmacological targeting of c-Abl and its downstream effector pathways may, therefore, represent a novel therapeutic approach to blocking TGF-beta-dependent fibrotic processes.

Citing Articles

Early growth response-1: Key mediators of cell death and novel targets for cardiovascular disease therapy.

Xie Y, Li Y, Chen J, Ding H, Zhang X Front Cardiovasc Med. 2023; 10:1162662.

PMID: 37057102 PMC: 10086247. DOI: 10.3389/fcvm.2023.1162662.

Specific targeting of PDGFRβ in the stroma inhibits growth and angiogenesis in tumors with high PDGF-BB expression.

Tsioumpekou M, Cunha S, Ma H, Ahgren A, Cedervall J, Olsson A Theranostics. 2020; 10(3):1122-1135.

PMID: 31938055 PMC: 6956815. DOI: 10.7150/thno.37851.

Inhibition of integrin αβ changes fibril thickness of stromal collagen in experimental carcinomas.

Olsson P, Gustafsson R, Salnikov A, Gothe M, Zeller K, Friman T Cell Commun Signal. 2018; 16(1):36.

PMID: 29966518 PMC: 6027735. DOI: 10.1186/s12964-018-0249-7.

Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib).

Wermuth P, Jimenez S PLoS One. 2018; 13(5):e0196559.

PMID: 29718973 PMC: 5931634. DOI: 10.1371/journal.pone.0196559.

Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease.

Martyanov V, Kim G, Hayes W, Du S, Ganguly B, Sy O PLoS One. 2017; 12(11):e0187580.

PMID: 29121645 PMC: 5679625. DOI: 10.1371/journal.pone.0187580.

References

Massague J, Seoane J, Wotton D . Smad transcription factors. Genes Dev. 2005; 19(23):2783-810. DOI: 10.1101/gad.1350705. View

Leask A . Targeting the TGFbeta, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma. Cell Signal. 2008; 20(8):1409-14. DOI: 10.1016/j.cellsig.2008.01.006. View

Bhattacharyya S, Chen S, Wu M, Warner-Blankenship M, Ning H, Lakos G . Smad-independent transforming growth factor-beta regulation of early growth response-1 and sustained expression in fibrosis: implications for scleroderma. Am J Pathol. 2008; 173(4):1085-99. PMC: 2543076. DOI: 10.2353/ajpath.2008.080382. View

Mori Y, Chen S, Varga J . Modulation of endogenous Smad expression in normal skin fibroblasts by transforming growth factor-beta. Exp Cell Res. 2000; 258(2):374-83. DOI: 10.1006/excr.2000.4930. View

Kharas M, Fruman D . ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res. 2005; 65(6):2047-53. DOI: 10.1158/0008-5472.CAN-04-3888. View

Wang S, Wilkes M, Leof E, Hirschberg R . Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J. 2005; 19(1):1-11. DOI: 10.1096/fj.04-2370com. View

Stuart J, Kawai H, Tsai K, Chuang E, Yuan Z . c-Abl regulates early growth response protein (EGR1) in response to oxidative stress. Oncogene. 2005; 24(55):8085-92. DOI: 10.1038/sj.onc.1208953. View

Raitano A, Halpern J, Hambuch T, Sawyers C . The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci U S A. 1995; 92(25):11746-50. PMC: 40479. DOI: 10.1073/pnas.92.25.11746. View

Lewis J, Baskaran R, Taagepera S, Schwartz M, Wang J . Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. Proc Natl Acad Sci U S A. 1996; 93(26):15174-9. PMC: 26376. DOI: 10.1073/pnas.93.26.15174. View

10.

Danial N, Rothman P . JAK-STAT signaling activated by Abl oncogenes. Oncogene. 2000; 19(21):2523-31. DOI: 10.1038/sj.onc.1203484. View

11.

Svaren J, Ehrig T, Abdulkadir S, Ehrengruber M, Watson M, Milbrandt J . EGR1 target genes in prostate carcinoma cells identified by microarray analysis. J Biol Chem. 2000; 275(49):38524-31. DOI: 10.1074/jbc.M005220200. View

12.

Bonner J . Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev. 2004; 15(4):255-73. DOI: 10.1016/j.cytogfr.2004.03.006. View

13.

Rosenbloom J, Jimenez S . Molecular ablation of transforming growth factor beta signaling pathways by tyrosine kinase inhibition: the coming of a promising new era in the treatment of tissue fibrosis. Arthritis Rheum. 2008; 58(8):2219-24. PMC: 2746747. DOI: 10.1002/art.23634. View

14.

Van Etten R . Cycling, stressed-out and nervous: cellular functions of c-Abl. Trends Cell Biol. 1999; 9(5):179-86. DOI: 10.1016/s0962-8924(99)01549-4. View

15.

Lakos G, Takagawa S, Chen S, Ferreira A, Han G, Masuda K . Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol. 2004; 165(1):203-17. PMC: 1618525. DOI: 10.1016/s0002-9440(10)63289-0. View

16.

Pannu J, Nakerakanti S, Smith E, Ten Dijke P, Trojanowska M . Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways. J Biol Chem. 2007; 282(14):10405-13. DOI: 10.1074/jbc.M611742200. View

17.

Lugo T, Pendergast A, Muller A, Witte O . Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990; 247(4946):1079-82. DOI: 10.1126/science.2408149. View

18.

Wilkes M, Leof E . Transforming growth factor beta activation of c-Abl is independent of receptor internalization and regulated by phosphatidylinositol 3-kinase and PAK2 in mesenchymal cultures. J Biol Chem. 2006; 281(38):27846-54. DOI: 10.1074/jbc.M603721200. View

19.

Miyazono K . TGF-beta receptors and signal transduction. Int J Hematol. 1997; 65(2):97-104. DOI: 10.1016/s0925-5710(96)00542-7. View

20.

Javelaud D, Mauviel A . Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis. Oncogene. 2005; 24(37):5742-50. DOI: 10.1038/sj.onc.1208928. View